The MIT Center for Collective Intelligence and MilliporeSigma brought together the thought-power of gurus in science, healthcare, public policy and other sectors to answer the question: how do we apply what we have learned from the COVID-19 pandemic for the future?
Massachusetts-based Kytopen has seen an influx of cash during the past few months. Most recently, the biotech raised a large chunk of money in the company’s Series A funding round, which was announced on Sept. 28.
Researchers at Massachusetts Institute of Technology (MIT) developed an artificial intelligence (AI) model able to detect asymptomatic Covid-19 cases by identifying differences in the sounds of coughs between healthy and infected people.
U.S. industrial conglomerate 3M Co. has partnered with the Massachusetts Institute of Technology to develop a rapid antigen test for COVID-19.
A hot, humid summer will slow coronavirus transmission but, on its own, is not likely to end the COVID-19 pandemic, according to a new study by researchers at the Massachusetts Institute of Technology, Harvard University, the University of Connecticut and Virginia Tech.
BioSpace reviews some recently published scientific studies, including researchers with the University of Colorado Anschutz Medical Campus releasing a new study calling attention to the emergence of mosquito-borne viral outbreaks in West Africa.
AbelsonTaylor participated in the MIT COVID-19 Challenge. The 48-hour virtual event hosted 1,500 hackers and created 238 teams to address COVID-19 challenges within 10 focus tracks. Participants came from more than 96 countries and 49 states, each dealing with different stages of COVID-19 in their communities and made for a richly diverse array of proposed solutions. Partners, sponsors and over 250 volunteer mentors worked the weekend to provide research and development resources to teams throughout.
The MIT COVID-19 Challenge was a 48-hour virtual event that hosted 1,500 hackers and created 238 teams to address COVID-19 challenges within 10 focus tracks.
A smart insulin device under development could revolutionize how glucose levels are monitored in diabetes patients and deliver insulin doses when necessary.
Scientists at the Broad Institute of MIT and Harvard tested about 4,518 drugs on 578 human cancer cell lines, and discovered that almost 50 had previously unrecognized anti-cancer properties.